Rexulti: adverse event reports filed with FDA

12,683

reports as suspect product

0.1% of all reports · about 1,162 a year

630

reports, 12 months to June 2026

1,332 in the 12 months before

32.3%

marked serious by the reporter

70.7% across the class

3.7%

record death among outcomes, as reported

464 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Rexulti reports recording the termmedian drug in atypical antipsychotic

1. Weight increasedweight gain12.2%1,552
2. Product use in unapproved indicationused for a purpose not on the label8.7%1,104
3. Off label useused for a purpose or in a way not on the label6.9%873
4. Akathisiainner restlessness and an urge to move6.1%778
5. Drug ineffectivethe medicine did not work as expected4.7%597
6. Tremorshaking4.3%543
7. Tardive dyskinesiainvoluntary repetitive movements4.2%535
8. Product use issuea problem in how the product was used3.5%450
9. Anxietyanxiety3.5%439
10. Feeling abnormalfeeling odd or not right3.1%393
11. Insomniadifficulty sleeping3%386
12. Depressionlow mood2.9%364
13. Suicidal ideationthoughts of suicide2.8%353
14. Inability to afford medication2.7%340
15. Restlessnessrestlessness2.4%305
16. Incorrect dose administeredthe wrong dose was given2.3%298
17. Fatiguetiredness2.3%294
18. Somnolencedrowsiness2.2%277
19. Dizzinesslight-headedness or unsteadiness2.2%274
20. Nauseafeeling sick2%255
21. Therapy cessation2%255
22. Headachehead pain1.9%245
23. Agitationrestlessness1.9%242
24. Falla fall1.9%240
25. Drug interactionan interaction between medicines1.8%231
26. Electrocardiogram QT prolongeda QT prolongation on the ECG1.6%204
27. Dyskinesiainvoluntary movements1.6%202
28. Wrong technique in product usage processthe product was used in the wrong way1.5%196
29. Condition aggravatedthe condition being treated got worse1.5%188
30. Insurance issue1.4%182

Top 30 of 812 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 37 drugs in the atypical antipsychotic class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 683,680 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 85.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 12,683 reports.

Drugs most often listed in the same reports

Other products listed in reports where Rexulti is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the atypical antipsychotic class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Rexulti as a suspect or interacting product; reports listing it only as a concomitant medication (1,924) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.